Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics

The heart of the matter: cardiometabolic care in youth with psychosis

(2012) Jackie Curtis et al.   Early Intervention in Psychiatry

Targeted Intervention to Improve Monitoring of Antipsychotic-Induced Weight Gain and Metabolic Disturbance in First Episode Psychosis

(2011) Andrew Thompson et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Atypical Antipsychotic-Induced Weight Gain

(2011) James L. Roerig et al.   CNS DRUGS

Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care

(2011) Patrick D McGorry et al.   CURRENT OPINION IN PSYCHIATRY

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

(2011) M. De Hert et al.   EUROPEAN PSYCHIATRY

Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study

(2011) G. Paul Amminger et al.   SCHIZOPHRENIA RESEARCH

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

(2009) Christoph U. Correll   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study

(2008) Linmarie Sikich et al.   AMERICAN JOURNAL OF PSYCHIATRY